Conference Coverage
Conference Coverage
Pregnancies with low anti-SSA/Ro autoantibody levels: Forgo fetal heart rhythm monitoring?
The ongoing prospective multicenter trial is the largest of its kind.
Conference Coverage
Sustained reductions in Lp(a) achieved with novel siRNA drug
“At the highest doses, lepodisiran is not just lowering Lp(a), it appears to be getting rid of it.”
Conference Coverage
Dropping aspirin cuts bleeding in LVAD patients: ARIES-HM3
“We’ve always thought that somehow aspirin prevents stroke and prevents clotting and that it’s anti-inflammatory, and what we found in ARIES was...
Conference Coverage
Potential dapagliflozin benefit post MI is not a ‘mandate’
“From my perspective, DAPA-MI does not suggest a new mandate to expand SGLT2 inhibition to an isolated MI population without other SGLT2 inhibitor...
Conference Coverage
Semaglutide ‘a new pathway’ to CVD risk reduction: SELECT
The SELECT trial was “a turning point in the treatment of obesity and a call to action.”
Conference Coverage
Angioplasty finally proven beneficial in stable angina: ORBITA-2
“I can say with confidence on the basis of a placebo-controlled trial that PCI certainly does have a favorable impact in patients with documented...
Conference Coverage
In MI with anemia, results may favor liberal transfusion: MINT
This study is “not a home run,” for the primary outcome, however, many of the outcomes tended to be in favor of a liberal transfusion strategy.
Conference Coverage
Women have worse outcomes in cardiogenic shock
“Our decision-making around women seems to be different to that around men. I think this paper should start to trigger more awareness of that.”
Conference Coverage
Short aspirin therapy noninferior to DAPT for 1 year after PCI for ACS
“This study provides evidence that stopping aspirin within 1 month after implantation of drug-eluting stents for ticagrelor monotherapy is a...
Conference Coverage
Stroke patients benefit from neurologic music therapy
Neurologic music therapy improves mental health and increases neuroplasticity, when used in conjunction with stroke rehabilitation.
Conference Coverage
Aprocitentan reduces resistant hypertension in CKD
Aprocitentan, a novel dual endothelin antagonist, showed antihypertensive efficacy and manageable safety in people with chronic kidney disease.